Aurinia Pharmaceuticals Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aurinia Pharmaceuticals stock.
View analyst ratings for Aurinia Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Aurinia Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aurinia Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Aurinia Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) released its quarterly earnings results on Wednesday, August, 4th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.02. The biotechnology company earned $6.62 million during the quarter, compared to the consensus estimate of $4.98 million. Aurinia Pharmaceuticals had a negative net margin of 242.26% and a negative trailing twelve-month return on equity of 36.98%.
View Aurinia Pharmaceuticals' earnings history.

Aurinia Pharmaceuticals' stock was trading at $14.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AUPH stock has increased by 48.9% and is now trading at $21.00.
View which stocks have been most impacted by COVID-19.

6 brokerages have issued 1 year price targets for Aurinia Pharmaceuticals' shares. Their forecasts range from $23.00 to $35.00. On average, they anticipate Aurinia Pharmaceuticals' share price to reach $29.60 in the next year. This suggests a possible upside of 41.0% from the stock's current price.
View analysts' price targets for Aurinia Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Aurinia Pharmaceuticals include Grifols (GRFS), CureVac (CVAC), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Ascendis Pharma A/S (ASND), United Therapeutics (UTHR), Biohaven Pharmaceutical (BHVN), Mirati Therapeutics (MRTX), Evotec (EVTCY), Jazz Pharmaceuticals (JAZZ), BridgeBio Pharma (BBIO), Sarepta Therapeutics (SRPT), Mawson Infrastructure Group (WIZP), Arrowhead Pharmaceuticals (ARWR) and HUTCHMED (HCM).
View all of AUPH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY).

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Aurinia Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (6.64%), Morgan Stanley (2.83%), Morgan Stanley (2.82%), Kingdon Capital Management L.L.C. (1.23%), Susquehanna International Group LLP (0.00%) and Wells Fargo & Company MN (0.61%). Company insiders that own Aurinia Pharmaceuticals stock include Jill Leversage, Joseph M Miller, Matthew Maxwell Donley, Michael Robert Martin, Neil Solomons, Peter Greenleaf, Robert Bindert Huizinga and Stephen P Robertson.
View institutional ownership trends for Aurinia Pharmaceuticals.

AUPH stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., Kingdon Capital Management L.L.C., SG3 Management LLC, Goldman Sachs Group Inc., Citadel Advisors LLC, Blackcrane Capital LLC, and Man Group plc. Company insiders that have sold Aurinia Pharmaceuticals company stock in the last year include Michael Robert Martin, Neil Solomons, and Robert Bindert Huizinga.
View insider buying and selling activity for Aurinia Pharmaceuticals or view top insider-selling stocks.

AUPH stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Susquehanna International Group LLP, Sector Gamma AS, Deutsche Bank AG, Group One Trading L.P., Simplex Trading LLC, and Stifel Financial Corp. Company insiders that have bought Aurinia Pharmaceuticals stock in the last two years include Jill Leversage, Joseph M Miller, Matthew Maxwell Donley, Peter Greenleaf, and Stephen P Robertson.
View insider buying and selling activity for Aurinia Pharmaceuticals or or view top insider-buying stocks.

Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AUPH stock can currently be purchased for approximately $21.00.

Aurinia Pharmaceuticals has a market capitalization of $2.70 billion and generates $50.12 million in revenue each year. The biotechnology company earns $-102,680,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis.

Aurinia Pharmaceuticals employs 294 workers across the globe.

The official website for Aurinia Pharmaceuticals is www.auriniapharma.com.

Aurinia Pharmaceuticals is headquartered at 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8.

Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via email at [email protected].